Cochlear Stock

Cochlear SGA/Revenue

The SGA to Revenue Ratio of Cochlear (COH.AX) as of Aug 22, 2026 is 40.11 %. In the previous year, SGA to Revenue Ratio was 40.15 % — a change of -0.09% (lower).

SGA/Revenue

40.11 %

YoY

-0.09%

Last updated:

SGA to Revenue Ratio of Cochlear is 2026 40.11 % . SGA to Revenue Ratio of Cochlear was 2025 40.15 % . It decreases by -0.09% lower compared to the previous year.

The Cochlear SGA/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

SGA/Revenue
Date
SGA/Revenue
Jan 1, 2018
36.25 AUD
Jan 1, 2019
38.25 AUD
Jan 1, 2020
42.69 AUD
Jan 1, 2021
37.15 AUD
Jan 1, 2022
39.90 AUD
Jan 1, 2023
41.86 AUD
Jan 1, 2024
40.15 AUD
Jan 1, 2025
40.11 AUD
The Cochlear SGA/Revenue history
YEARSGA/RevenueYoY
40.11 %-0.09%
40.15 %-4.08%
41.86 %+4.90%
39.90 %+7.42%
37.15 %-12.99%
42.69 %+11.62%
38.25 %+5.50%
36.25 %+5.69%
34.30 %-4.33%
35.86 %+3.61%
34.61 %-0.12%
34.65 %
Access this data via the Eulerpool API

Cochlear Stock analysis

What does Cochlear do? Cochlear Ltd is an Australian-based medical technology company founded in 1981 by engineer Professor Graeme Clark. The company specializes in Cochlear implant systems and other hearing devices. Cochlear Ltd offers accessories, services, and rehabilitation training for individuals with hearing impairments. The company's products are available for both children and adults with varying degrees of hearing loss. Cochlear Ltd operates in different sectors, including Cochlear implant systems, hearing aids, and wireless accessories and streaming systems under the brand names Nucleus® and Baha®. Nucleus® systems utilize a fully implantable cochlear implant and external speech processor to convert sound into electrical signals for interpretation by the brain. Baha® systems are bone-anchored hearing devices for individuals with unilateral to moderate hearing impairments. Cochlear Ltd also provides wireless accessories and streaming systems to connect devices like mobile phones, TVs, and music players to the hearing aids and cochlear implants, improving hearing performance and enhancing social lives. The company has a strong global presence, operating in over 100 countries with headquarters in Australia, multiple production facilities, and research centers. Cochlear Ltd has received numerous awards and recognition for its products and services and is committed to researching and developing new therapies and technologies to improve the lives of individuals with hearing impairments. Cochlear is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cochlear stock

SGA to Revenue Ratio of Cochlear is 40.11 % in 2026.

SGA to Revenue Ratio of Cochlear changed from 40.15 % to 40.11 %, representing a -0.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of SGA to Revenue Ratio Cochlear since 2006 – with annual values, charts, and detailed analysis.

The SGA/Revenue ratio shows what percentage of revenue is consumed by selling, general, and administrative costs. Lower ratios indicate greater operating efficiency.

A 'good' varies by industry and company stage. On Eulerpool, you can compare SGA to Revenue Ratio's Cochlear with sector peers and the industry average to assess whether it is attractive.

To evaluate SGA to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for SGA to Revenue Ratio.

Access this data via the Eulerpool API

Margins — Cochlear

All Key Metrics — Cochlear